2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2016
Endobronchial Ultrasound-Guided Cautery-Assisted Transbronchial Forceps Biopsies: Safety and Sensitivity Relative to Transbronchial Needle Aspiration
Bramley K, Pisani MA, Murphy TE, Araujo KL, Homer RJ, Puchalski JT. Endobronchial Ultrasound-Guided Cautery-Assisted Transbronchial Forceps Biopsies: Safety and Sensitivity Relative to Transbronchial Needle Aspiration. The Annals Of Thoracic Surgery 2016, 101: 1870-1876. PMID: 26912301, PMCID: PMC4861078, DOI: 10.1016/j.athoracsur.2015.11.051.Peer-Reviewed Original ResearchConceptsTransbronchial needle aspirationTransbronchial forceps biopsyForceps biopsyClinical trialsEndobronchial ultrasoundNeedle aspirationConvex probe EBUSSignificant adverse eventsDiagnosis of sarcoidosisExcellent diagnostic yieldSelect clinical scenariosSequential useTBNA samplesSecondary outcomesUnselected patientsAdverse eventsLymph nodesThoracic lymphadenopathyEBUS guidanceGranulomatous inflammationCore biopsyGranulomatous diseaseAdequate specimensNeedle biopsyDiagnostic yield